Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 9/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25407145 | 0.85 | MAPT (0.51) | PTPN1KDM4ESMN1; SMN2 | |
| SCHEMBL2694549 | 0.81 | PTPN1 (0.57) | MGAMPTPN1 | |
| SCHEMBL22468592 | 0.79 | PTPN1 (0.59) | PTPN1MRGPRX4KDM4ESMN1; SMN2 | |
| SCHEMBL25408552 | 0.78 | ALDH1A1 (0.58) | KDM4ESMN1; SMN2 | |
| SCHEMBL25410521 | 0.77 | PTPN1 (0.41) | PTPN1KDM4ESMN1; SMN2 | |
| SCHEMBL4307200 | 0.76 | MGAM (0.53) | MGAMMRGPRX4CNR2KDM4E | |
| SCHEMBL31329134 | 0.76 | MGAM (0.53) | MGAMMRGPRX4CNR2KDM4E | |
| SCHEMBL8419113 | 0.76 | SRD5A2 (0.45) | PTPN1SMN1; SMN2 | |
| SCHEMBL12458277 | 0.73 | MGAM (0.53) | MGAMCNR2KDM4E | |
| SCHEMBL5893048 | 0.73 | RXRA (0.46) | PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023164680-A1 | 6-OXODECAHYDROPYRROLO[1,2-A][1,5]DIAZOCINE AND 6-OXODECAHYDRO-4H-PYRROLO[2,1-D][1,5]THIAZOCINE DERIVATIVES AS STAT3 AND STAT6 MODULATORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS | RECLUDIX PHARMA, INC. (US) | 2023-08-31 | — | — | WO | disclosed |